Mineralys Therapeutics, Inc. (MLYS)
| Market Cap | 2.26B +124.4% |
| Revenue (ttm) | n/a |
| Net Income | -349.58M |
| EPS | -4.38 |
| Shares Out | 88.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 812,833 |
| Open | 25.81 |
| Previous Close | 26.01 |
| Day's Range | 25.25 - 26.11 |
| 52-Week Range | 14.94 - 47.65 |
| Beta | 0.68 |
| Analysts | Strong Buy |
| Price Target | 48.50 (+89.45%) |
| Earnings Date | Aug 11, 2026 |
About MLYS
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Minera... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for MLYS stock is "Strong Buy." The 12-month stock price target is $48.5, which is an increase of 89.45% from the latest price.
News
Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics reports Q2 EPS ($2.85), consensus (54c)
Research and development expenses for the quarter ended June 30 were $221.4M, compared to $38.3M for the quarter ended June 30, 2025. The increase in R&D expenses was primarily due…
Mineralys Therapeutics price target lowered to $49 from $51 at BofA
BofA lowered the firm’s price target on Mineralys Therapeutics (MLYS) to $49 from $51 and keeps a Buy rating on the shares. The firm’s lower target is driven by lowering…
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw major investments in launch readiness, clinical progress, and capital structure, with lorundrostat positioned for a December PDUFA. Strong cash reserves support operations into 2028, while payer and market feedback remain positive for commercial success.
Mineralys Therapeutics Earnings release: Q2 2026
Mineralys Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Mineralys Therapeutics Quarterly report: Q2 2026
Mineralys Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
– PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for launch upon approval – – Appoints accomplished cardiovascular medicine executive Dr. Terry Ferguson as C...
Mineralys Therapeutics Slides: Corporate presentation
Mineralys Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
RADNOR, Pa., July 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related a...
Mineralys Therapeutics presents late-breaking data on lorundrostat
Mineralys Therapeutics (MLYS) presented new data on the effect of lorundrostat on heart failure risk biomarkers. This post hoc analysis of circulating proteomic data from participants enrolled in the ...
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –
Mineralys Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Lorundrostat’s NDA is under FDA review with a December PDUFA date, and preparations for launch are well underway, including a strategic royalty buyback and new financing. Recent clinical data support efficacy and safety in both CKD and non-CKD patients, and market access is expected to begin in fourth-line hypertension with rapid expansion.
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbiditie...
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
Late-breaking presentation reports a proteomic analysis of heart failure biomarkers during lorundrostat treatment Late-breaking presentation reports a proteomic analysis of heart failure biomarkers du...
Mineralys Therapeutics falls -17.1%
Mineralys Therapeutics (MLYS) is down -17.1%, or -$4.93 to $23.92.
Mineralys Therapeutics falls -12.7%
Mineralys Therapeutics (MLYS) is down -12.7%, or -$3.67 to $25.18.
Mineralys prices offering of 5.66M shares of common stock at $26.50
Mineralys Therapeutics (MLYS) announced the pricing of an underwritten offering of 5.66M shares of its common stock at a price of $26.50 per share. The aggregate gross proceeds to Mineralys…
Mineralys Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Significant financial transactions have fully funded commercialization plans for lorundrostat, a selective aldosterone synthase inhibitor targeting uncontrolled and resistant hypertension. Clinical trials show robust efficacy and safety, with strong physician interest and a large addressable market of 20 million U.S. patients.
Mineralys to repurchase future royalty payments in Tanabe license agreement
Mineralys Therapeutics (MLYS) announced the repurchase of all potential future royalty payments due to Tanabe Pharma Corporation related to lorundrostat in exchange for a $200M upfront payment and up ...
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
RADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
– Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met –
Mineralys Therapeutics presents new data for lorundrostat
Mineralys Therapeutics (MLYS) presented new clinical data for lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection in Gdansk, Poland. The analysis evaluated the effi...
Mineralys' pill cuts blood pressure in kidney disease patients
Mineralys Therapeutics' experimental drug significantly reduced blood pressure in patients with chronic kidney disease, according to new data presented at a major European medical conference on Satur...
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease –